Ticker AGLE – Aeglea Bio Therapeutics – sales, description, marketcap – Tickerday.com

AGLE

Aeglea Bio Therapeutics

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 318.44M; Volume: 50.42K; AvgVol 3m: 237.15K; Beta: 1.80;

Cost estimate:

P/E: –; EPS: -2.28; EPS growth quarter/prev quarter: 26.30%;

EPS growth this year: -15.00%; EPS growth past 5 years: -22.00%;

EPS ttm: -2.28;

P/S: ; P/B: 2.59; P/Cashflow: 2.36; P/FCF: ;

Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -79.10%; ROE – return on equity: -99.40%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 1.20%; Insider Transactions:38.13%;

Institutional Ownership: 92.70%; Institutional Transactions: 61.99%;

Data update: 07.10.2020.